Clinical Trials

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms

NCT07217496 2026-03-17

N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial Cancer

Phase 1 Withdrawn

Phase 2 Not yet recruiting

Carcinoma, Transitional Cell

NCT07475806 2026-03-17

A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder

240 enrolled

Muscle-invasive Bladder Cancer

NCT03547973 2026-03-16

TROPHY U-01

827 enrolled 1 FDA

Metastatic Urothelial Cancer

NCT07232602 2026-03-16

MK-3475-04D

55 enrolled

Urinary Bladder Neoplasms

NCT07287995 2026-03-16

A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors

BreastGenitourinaryThoracic

428 enrolled

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell

NCT06862219 2026-03-06

A Safety Study of Enfortumab Vedotin in Indian Adults With Urothelial Cancer

Phase 4 Recruiting

100 enrolled

Carcinoma, Transitional Cell

NCT06434350 2026-03-02

Enfortumab Vedotin With Radiation for Locally Advanced Bladder Cancer (CONSOLIDATE)

41 enrolled

Advanced Bladder Cancer

NCT06809140 2026-02-23

Enfortumab Vedotin Plus Pembrolizumab With Selective Bladder Sparing for Treatment of Muscle-invasive Bladder Cancer

47 enrolled

Muscle Invasive Bladder Urothelial Carcinoma

NCT05239624 2026-02-19

Enfortumab Vedotin and Pembrolizumab in People With Bladder Cancer

23 enrolled

Carcinoma, Transitional Cell

NCT07221942 2026-02-19

IMPROEV

97 enrolled

Phase 1/2 Not yet recruiting

Carcinoma, Transitional Cell

NCT07421700 2026-02-19

A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer

132 enrolled

Phase 1/2 Active not recruiting

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT06483334 2026-02-18

MK-3475-04C

38 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Transitional Cell

NCT05868265 2026-02-17

A Study of Enfortumab Vedotin in People With Urothelial Carcinoma of the Upper Urinary Tract

24 enrolled

Carcinoma, Transitional Cell

NCT06724159 2026-02-17

SOGUG-PRINCIS

Recruiting

500 enrolled

Phase 2 Active not recruiting

Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Urogenital Neoplasms

NCT04754191 2026-02-12

ENCORE

34 enrolled

Metastatic Castration-resistant Prostate Cancer

NCT06764095 2026-02-12

Enfortumab Vedotin and Pembrolizumab With Cystectomy and/or Ureterectomy for Locally Advanced or Metastatic Bladder and Upper Urothelial Tract Cancer, CAST-AI Trial

Phase 4 Recruiting

75 enrolled

Urinary Bladder Neoplasms, Ureteral Neoplasms

NCT04700124 2026-02-05

KEYNOTE-B15

Phase 3 Completed

808 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Urinary Bladder Neoplasms

NCT05775471 2026-02-05

Pembrolizumab and Enfortumab Vedotin With Pembrolizumab Prior to and After Radical Nephroureterectomy for High-Risk Upper Tract Urothelial Cancer

21 enrolled

Renal Pelvis and Ureter Urothelial Carcinoma

NCT07183319 2026-02-02

Circulating Tumor DNA Response In Urothelial Cancer

30 enrolled

Carcinoma, Transitional Cell, Neoplasm Metastasis

NCT03869190 2026-01-22

Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)

Phase 1/2 Completed

272 enrolled

Phase 3 Not yet recruiting

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT07346053 2026-01-16

Chrono-EVP

224 enrolled

Advanced Bladder Cancer

NCT07110038 2026-01-12

DEPECA-1 - A Phase II Study to Evaluate a First-line Systemic Therapy With Enfortumab Vedotin Plus Avelumab for Advanced and Metastatic Penile Carcinoma

25 enrolled

608 enrolled 22 charts 1 FDA

Penile Squamous Cell Carcinoma (PSCC)

NCT03474107 2026-01-09

A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)

Phase 3 Completed

Urinary Bladder Neoplasms, Ureteral Neoplasms

NCT05656235 2026-01-08

Renal Retention in High Grade Upper Tract Urothelial Cancer

20 enrolled

Phase 3 Active not recruiting

Urinary Bladder Neoplasms

NCT04960709 2025-12-19

VOLGA

712 enrolled

Urinary Bladder Neoplasms

NCT06104618 2025-12-11

Enfortumab Vedotin for the Treatment of Patients With Metastatic or Unresectable Squamous Cell Carcinoma of the Penis

28 enrolled

Penile Neoplasms

NCT07087860 2025-12-09

RECIPE-B1

70 enrolled

Urinary Bladder Neoplasms, Ureteral Neoplasms

NCT05014139 2025-11-20

A Study of Intravesical Enfortumab Vedotin For Treatment of Patients With Non-muscle Invasive Bladder Cancer (NMIBC)

Phase 1 Terminated

37 enrolled

Phase 1/2 Active not recruiting

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma, Transitional Cell

NCT03288545 2025-11-10

EV-103

348 enrolled 1 FDA

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms, Urologic Neoplasms

NCT05923190 2025-10-29

Enfortumab Vedotin Schedule De-escalation in Metastatic Urothelial Carcinoma

70 enrolled

Carcinoma, Transitional Cell

NCT04995419 2025-10-07

A Study to Evaluate Enfortumab Vedotin (ASG-22CE) in Chinese Participants With Locally Advanced or Metastatic Urothelial Cancer Who Previously Received Platinum-containing Chemotherapy and Programmed Cell Death Protein-1 ( PD 1) / (Programmed Death Ligand-1 (PD-L1) Inhibitor Therapy

Phase 2 Completed

40 enrolled 34 charts

Metastatic Urothelial Cancer

NCT06394570 2025-09-15

STAR-EV

19 enrolled

Urinary Bladder Neoplasms

NCT06302569 2025-09-09

REPRINT

23 enrolled

Carcinoma, Renal Cell

NCT05756569 2025-07-28

Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology

25 enrolled

Urachal adenocarcinoma, Urinary Bladder Neoplasms, Ureteral Neoplasms

NCT05524545 2025-07-25

A Study of Evorpacept (ALX148) With Enfortumab Vedotin for Subjects With Urothelial Carcinoma (ASPEN-07)

Phase 1 Completed

36 enrolled

Phase 3 Active not recruiting

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT04223856 2025-06-13

EV-302

886 enrolled 12 charts 1 FDA

Urothelial Cancer

NCT06493552 2025-04-03

Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors

Phase 2/3 Recruiting

700 enrolled

GenitourinaryOther solid neoplasm

Carcinoma, Transitional Cell

NCT02091999 2024-11-01

A Study of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects With Metastatic Urothelial Cancer and Other Malignant Solid Tumors That Express Nectin-4

Phase 1 Completed

213 enrolled

Metastatic Urothelial Cancer and Other Malignant Solid Tumors

NCT03070990 2024-10-18

A Study of Enfortumab Vedotin in Japanese Subjects With Locally Advanced or Metastatic Urothelial Carcinoma

Phase 1 Completed

19 enrolled

219 enrolled 32 charts 2 FDA

Carcinoma, Transitional Cell

NCT03219333 2024-08-27

EV-201

Phase 2 Completed

Phase EARLY_PHASE1 Unknown

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms, Urologic Neoplasms

NCT06204614 2024-01-12

Drug Screening Using IMD in Bladder Cancer

18 enrolled

Muscle Invasive Bladder Urothelial Carcinoma

NCT03606174 2023-08-24

A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma

Phase 2 Terminated

260 enrolled 28 charts

Carcinoma, Transitional Cell

NCT04136808 2020-01-13

An Expanded Access Treatment Protocol of Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Urothelial Carcinoma

Approved for marketing